by Kevin Dooley, MD | Mar 27, 2020 | News and Information
Thomas Blaettler, MD, the Chief Medical Office of Orphazyme, has released a statement to the global community regarding the status of the ongoing arimoclomol clinical trials during the coronavirus (COVID-19) pandemic. Arimoclomol is currently being studied for... 
by Kevin Dooley, MD | Mar 20, 2020 | News and Information
The following is a message written by Tom Lloyd, MD, a myositis specialist at the Johns Hopkins Medical Center. Can Chloroquine Cure Coronavirus? Not so fast… In a press conference today, President Trump discussed what the FDA was doing to accelerate approval of... 
by Kevin Dooley, MD | Mar 19, 2020 | News and Information
AAVogen, an early-stage biotech company, is developing a new treatment for inclusion body myositis (IBM). AVGN7 is a novel gene therapy treatment that is designed to treat IBM and other muscle wasting conditions. AAVogen has raised $2.3 million to date, mostly from...